

Topical Collection

Novel Biomarkers and Molecular Targets in Cancer

Message from the Collection Editor

Today, the discovery of novel biomarkers and molecular targets to fight cancer remains the matter of great importance. Recent novel techniques, including cancer mutational analysis, genomics, proteomics and metabolomics, have given rise to new efforts in performing pathological, biochemical, molecular, and immunological research to study the mechanisms of carcinogenesis, with the final aim of finding the cancer molecular targets, which could be applied in clinical practice. This Special Issue aims to present the most recent studies related to the discovery of novel biomarkers and molecular targets in various cancers. The research could be performed in different aspects, including: 1) genetic alterations in cancer, 2) diagnosis using novel techniques, 3) cancer molecular mechanisms, 4) in vitro and in vivo carcinogenesis models for the discovery of cancer risk factors and innovative drugs to treat cancer, 5) cancer metabolic and proteomic signatures and altered pathways, 6) stem, stromal and immune cell biomarkers in cancer, and 7) preclinical innovative studies.

Collection Editor

Dr. Anna Kakehashi

Department of Molecular Pathology, Graduate School of Medicine,
Osaka Metropolitan University, Osaka 545-8585, Japan



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/42704

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)